<DOC>
	<DOCNO>NCT03099486</DOCNO>
	<brief_summary>This single arm open label pilot phase II trial Regorafenib PO plus 5-FU/LV infusion 15 mCRC patient progress prior Regorafenib monotherapy well 5-FU contain chemotherapy combinations.The study enroll mCRC patient prior progression standard multi-agent combination chemotherapy progression regorafenib monotherapy .</brief_summary>
	<brief_title>Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression mCRC</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. mCRC prior progression standard multiagent combination chemotherapy regorafenib standard approve monotherapy . Progression prior regorafenib require inclusion clinical study . Prior regimens may include FOLFOX /+ bevacizumab , FOLFIRI /+ bevacizumab /+ cetuximab ( KRAS wildtype ) panitumumab ( KRAS wilttype ) . Other prior regimen may include 5FU capecitabine /+ bevacizumab , irinotecan /+ cetuximab panitumumab , FOLFIRI /+ zivaflibercept ramucirumab . 2 . Patients treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy . Patients progress 6 month completion oxaliplatin contain adjuvant treatment must retreat . Patients withdrawn standard treatment due unacceptable toxicity warrant discontinuation treatment preclude retreatment agent prior progression disease also allow study . 3 . Patients previously treat chemotherapy must least 4 week period last dose previous chemotherapy first dose clinical study . Patients previously treat biologics Avastin , Zaltrap , Erbitux , Vectibix must least 6 week period last dose previous chemotherapy first dose clinical study . 4 . Measurable metastatic disease refractory . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Patients include regardless KRAS/NRAS , BRAF , p53 , microsatellite instability ( MSI ) status 7 . Age ≥ 18 year . 8 . Life expectancy least 8 week ( 2 month ) . 9 . Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . 10 . Adequate bone marrow , liver renal function assess follow laboratory requirement : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Alkaline phosphatase limit ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Serum creatinine ≤ 1.5 x ULN International normalize ratio ( INR ) / Partial thromboplastin time ( PTT ) ≤ 1.5 x ULN . Platelet count &gt; 100000 /mm3 , hemoglobin ( Hb ) &gt; 9 g/dL , absolute neutrophil count ( ANC ) ≥ 1500/mm3 . Blood transfusion meet inclusion criterion allow . 11 . Subject must able swallow retain oral medication . 12 . Up 5 15 patient allow approved investigational drug prior progression Regorafenib monotherapy . ( patient enrol trial must prior progression regorafenib therapy ) . This may include TAS102 , offlabel therapy may prescribe base tumor genomic profile investigational agent clinical trial . 13 . No grade 2 toxicity last previous cycle regorafenib mono therapy . 1 . Patients receive concurrent investigational agent 2 . Previous assignment treatment study . Subjects permanently withdraw study participation allow reenter study . 3 . Uncontrolled hypertension ( systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg [ NCICTCAE v4.0 ] repeat measurement ) despite optimal medical management . 4 . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Suspected Long QT syndrome define QTc interval &gt; 500 millisecond baseline . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . 5 . Evidence history bleed diathesis coagulopathy . 6 . Any hemorrhage bleeding event ≥ NCI CTCAE Grade 3 within 4 week prior start study medication . 7 . Subjects diagnose thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) deep vein thrombosis pulmonary embolism within 3 month start study treatment . 8 . Patients previously untreated concurrent cancer distinct primary site histology except cervical cancer insitu , treat ductal carcinoma situ breast , curatively treat nonmelanoma skin carcinoma , noninvasive aerodigestive neoplasm , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year registration allow ; cancer treatment must complete least 3 year prior registration . 9 . Patients phaeochromocytoma . 10 . Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . 11 . Ongoing infection &gt; Grade 2 NCICTCAE v4.0 . 12 . Symptomatic metastatic brain meningeal tumor . 13 . Presence nonhealing wound , nonhealing ulcer , bone fracture . 14 . Major surgical procedure significant traumatic injury within 28 day start study medication 15 . Renal failure require hemoor peritoneal dialysis . 16 . Dehydration Grade ≥1 NCICTCAE v4.0 . 17 . Patients seizure disorder require medication . 18 . Persistent proteinuria ≥ Grade 3 per NCICTCAE v4.0 ( &gt; 3.5 g/24 hr , measure urine protein : creatinine ratio random urine sample ) . 19 . Interstitial lung disease ongoing sign symptoms time informed consent . 20 . Pleural effusion ascites cause respiratory compromise ( ≥ NCICTCAE version 4.0 Grade 2 dyspnea ) . 21 . History organ allograft ( include corneal transplant ) . 22 . Known suspected allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . 23 . Any malabsorption condition . 24 . Women pregnant breastfeeding . 25 . Any condition , investigator 's opinion , make subject unsuitable trial participation . 26 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result . 27 . Therapeutic anticoagulation VitaminK antagonist ( e.g. , warfarin ) heparins heparinoids . . However , prophylactic anticoagulation describe allow : . Low dose warfarin ( 1 mg orally , daily ) PTINR ≤ 1.5 x ULN permit . ii . Low dose aspirin ( ≤ 100 mg daily ) . iii . Prophylactic dos heparin . iv . Low molecular weight heparin Subjects prophylactically treat agent warfarin heparin require close monitoring ( day5 cycle 1 day 1 cycle ) INR/PTT . If either value therapeutic range , dose modified assessment repeat weekly stable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>